WuXi PharmaTech (Cayman) Inc. has announced that Edward Hu will serve as the new Chief Investment Officer in addition to his current role as Chief Financial Officer.
Hu will be responsible for companywide investments, including strategic investments in new businesses, corporate venture capital investments, mergers and acquisitions, and joint ventures. He has served as the company's Chief Operating Officer since January 2008 and as Chief Financial Officer since February 2009. He spearheaded efforts to build many of the company's new businesses, including biologics, toxicology, genomics, and clinical trial services in China.
He led the acquisition and integration of AppTec, Abgent, and MedKey. He also created and has managed WuXi's joint ventures with MedImmune to co-develop an innovative biologics product in China, and with PRA to create a clinical CRO in China that meets the highest international standards.